The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA’s Medical Devices Advisory Committee has strongly recommended FDA approval of Guardant Health’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
Clinical Roundup

Antibody-drug conjugate targeting CEACAM5 shows activity in advanced CRC in phase I study preliminary data

Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Drugs & Targets

FDA approves imetelstat for low- to intermediate-1 risk MDS with transfusion-dependent anemia

FDA approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account